PhaseBio Pharmaceuticals Inc. (PHAS) and Forward Pharma A/S (NASDAQ:FWP) Comparison side by side

PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and Forward Pharma A/S (NASDAQ:FWP) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PhaseBio Pharmaceuticals Inc. N/A 176.65 21.51M -1.02 0.00
Forward Pharma A/S N/A 0.00 29.41M -0.28 0.00

Demonstrates PhaseBio Pharmaceuticals Inc. and Forward Pharma A/S earnings per share (EPS), top-line revenue and valuation.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
PhaseBio Pharmaceuticals Inc. 0.00% 0% 0%
Forward Pharma A/S 0.00% -7.8% -6.5%


PhaseBio Pharmaceuticals Inc. has a Current Ratio of 3.2 and a Quick Ratio of 3.2. Competitively, Forward Pharma A/S’s Current Ratio is 17.2 and has 17.2 Quick Ratio. Forward Pharma A/S’s better ability to pay short and long-term obligations than PhaseBio Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both PhaseBio Pharmaceuticals Inc. and Forward Pharma A/S are owned by institutional investors at 52.36% and 18.8% respectively. Insiders held roughly 0.1% of PhaseBio Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PhaseBio Pharmaceuticals Inc. 28.77% -28.18% 0% 0% 0% -26.6%
Forward Pharma A/S -7.27% -40.35% -68.13% -63.31% -75% -72.28%

For the past year PhaseBio Pharmaceuticals Inc. was less bearish than Forward Pharma A/S.


PhaseBio Pharmaceuticals Inc. beats on 5 of the 7 factors Forward Pharma A/S.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.